Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Samankaltaisia teoksia

• Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
  Tekijä: Cavalli, Giulio, et al.
  Julkaistu: (2019)
• Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
  Tekijä: Cavalli, Giulio, et al.
  Julkaistu: (2020)
• Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients
  Tekijä: Cavalli, Giulio, et al.
  Julkaistu: (2020)
• Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
  Tekijä: Tomelleri, Alessandro, et al.
  Julkaistu: (2018)
• Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
  Tekijä: De Luca, Giacomo, et al.
  Julkaistu: (2021)